Limited Competition for the Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers (T1DAPC-CCs) (U01 Clinical Trial Optional)
ID: 356114Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $350K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356114

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-017.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a limited competition funding opportunity for the continuation of the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC), specifically for Clinical Centers (U01 Clinical Trial Optional). This initiative aims to establish a clinical consortium to conduct a longitudinal observational study on the incidence and mechanisms of diabetes, particularly type 1 diabetes (T1D), following episodes of acute pancreatitis, with a focus on identifying immune and genetic risk factors in a diverse population. The NIH anticipates funding of up to $5 million for fiscal year 2025, with individual applications allowed a budget of $350,000 per year over a maximum project period of five years. Interested applicants must adhere to strict guidelines and submit their proposals by November 19, 2024, with further inquiries directed to grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DK-25-017-Full-Announcement.html
    RFA-DK-25-017.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a limited competition funding opportunity for the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC). The aim is to continue a longitudinal study, known as the DREAM study, investigating the incidence and mechanisms of diabetes following acute pancreatitis episodes, with a focus on type 1 diabetes (T1D). This continuation is open only to current clinical centers funded under RFA-DK-19-022. Funding of up to $5 million is anticipated for the fiscal year 2025, with each application allowed a budget of $350,000 per year over a maximum project period of five years. The study seeks to monitor 1,000 adult participants, assessing diabetes status and related biomarkers, while recruiting efforts are intended to reflect the diversity of the U.S. population. Applications must conform to strict guidelines set forth in this notice to ensure compliance and may only originate from eligible institutions. The review process will evaluate the significance, investigator qualifications, innovation, and approach of submitted applications, emphasizing collaborative efforts and adherence to the T1DAPC protocols. This funding initiative underscores the NIH's commitment to advancing diabetes research through rigorous scientific inquiry and multidisciplinary collaboration.
    Similar Opportunities
    Single Source for the Continuation of the Type 1 Diabetes in Acute Pancreatitis Consortium - Data Coordinating Center (T1DAPC-DCC) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is soliciting applications for a cooperative agreement to establish the Type 1 Diabetes in Acute Pancreatitis Consortium Data Coordinating Center (T1DAPC-DCC). The primary objective is to conduct a longitudinal observational study, known as the DREAM study, which will investigate the incidence and mechanisms of diabetes that develop following episodes of acute pancreatitis. This initiative is crucial for understanding the relationship between acute pancreatitis and the onset of diabetes, particularly type 1 diabetes, and aims to identify genetic and environmental risk factors in a diverse population. Interested applicants must submit their proposals by November 19, 2024, with a funding ceiling of $800,000, and can direct inquiries to grantsinfo@nih.gov for further information.
    Single Source for the Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D) (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for a cooperative agreement to support the continuation of the Human Pancreas Analysis Program for Type 1 Diabetes (HPAP-T1D) at the University of Pennsylvania. This initiative aims to enhance research on Type 1 Diabetes by systematically collecting and analyzing human pancreatic tissues and immune cells from patients, thereby advancing the understanding of disease mechanisms and identifying potential biomarkers for early intervention. The program is critical for fostering collaborative translational research within the Human Islet Research Network, which seeks innovative strategies to protect and replace functional human beta cell mass. The total funding available is $7.5 million over four years, with applications due by October 24, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Coordinating Center for Type 1 Diabetes TrialNet (TNCC) through a cooperative agreement, aimed at supporting research initiatives focused on the prevention and intervention of type 1 diabetes (T1D). The TNCC will manage a variety of research projects, oversee data and sample management, and facilitate the selection of clinical centers necessary for conducting clinical studies related to T1D. This initiative underscores the federal commitment to advancing T1D research and treatment, with a total funding availability of approximately $29.5 million. Interested applicants must submit their proposals by October 17, 2024, and are required to include a Plan for Enhancing Diverse Perspectives (PEDP) as part of their application. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    The Chronic Pancreatitis Clinical Research Consortium (CPCRC)- Clinical Centers (CPCRC-CCs) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Chronic Pancreatitis Clinical Research Consortium (CPCRC), inviting U01 applications for Clinical Centers to conduct research on chronic pancreatitis, diabetes, and pancreatic cancer. The initiative aims to continue the consortium's work by collecting clinical data and biospecimens to identify biomarkers for risk stratification and disease progression, ultimately enhancing understanding and treatment of these conditions. With an estimated funding of $6.5 million for the 2025 fiscal year, applications are due by October 18, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), aimed at enhancing clinical trials focused on the prevention and early intervention of Type 1 Diabetes (T1D). The HUB will coordinate operations across various clinical centers to improve participant screening, recruitment, and retention, with a specific emphasis on increasing diversity among participants, particularly from minority populations. This initiative is critical for addressing the rising incidence of T1D and ensuring inclusivity in research efforts. The funding opportunity has an estimated budget of $750,000 per year from a total allocation of $1,000,000, with a maximum project duration of five years. Applications will be accepted starting September 16, 2024, and must include a Plan for Enhancing Diverse Perspectives (PEDP) to be considered complete. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Single Source for Chronic Pancreatitis Clinical Research Consortium (CPCRC) Data Coordinating Center (CPCRC-DCC) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement for the establishment of the Chronic Pancreatitis Clinical Research Consortium Data Coordinating Center (CPCRC-DCC) under funding opportunity RFA-DK-25-020. The primary objective is to facilitate ongoing studies on chronic pancreatitis, diabetes, and pancreatic cancer, focusing on data management, biomarker development, and clinical trial support for both pediatric and adult populations. This initiative is crucial for advancing the understanding of chronic pancreatitis and its associations with diabetes and pancreatic cancer, with an anticipated funding amount of $6.5 million over five years. Interested applicants must submit their proposals by 5:00 PM on October 19, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk observational studies related to diabetes, digestive, kidney, and metabolic diseases. Applicants must complete all planning activities prior to submission, as these cannot be included in the U01 application, and a Plan for Enhancing Diverse Perspectives (PEDP) is mandatory for consideration. This funding opportunity is crucial for advancing clinical research and addressing health disparities, particularly by encouraging collaboration with underrepresented communities. Interested applicants should note that the application deadline is February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity for high-risk multi-center clinical study implementation planning via Cooperative Agreements (U34). This initiative aims to support the early peer review of proposed clinical studies, assess study designs, and develop essential documentation, including operational manuals, focusing on diseases relevant to NIDDK's mission. The program emphasizes health equity and inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested applicants can apply for up to $225,000 per year for a maximum of two years, with the application submission period opening on September 9, 2024, and the closing date set for June 10, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting investigator-initiated, high-risk clinical trials that involve multiple clinical centers. Applicants must propose hypothesis-driven studies that focus on diseases relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with an emphasis on enhancing diverse perspectives in research. This funding opportunity is crucial for advancing therapeutic studies that can significantly improve clinical practices and public health outcomes. Interested applicants should note that the application period opens on January 5, 2024, with a closing date of November 5, 2026, and are encouraged to consult with NIDDK staff prior to submission. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small Research Project Grants (R01s) aimed at clinical trials focused on diseases under the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative encourages the submission of pilot and feasibility clinical trials that will provide foundational data for larger, definitive trials intended to improve the prevention and treatment of various health conditions, without the requirement of preliminary efficacy data. The program supports innovative research ideas and emphasizes equitable recruitment from diverse populations, with a maximum grant duration of three years and funding up to $200,000 per year. Interested applicants can find more information and submit their applications by May 7, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.